Ethyl-6-Fluoro-1-Methyl-4-Oxo-7-(1-Piprazinyl)-4H-(1,3)Thiazole(3,2-A)Quinoline-3-Carboxylate

The compound designated as Ethyl-6-Fluoro-1-Methyl-4-Oxo-7-(1-Piperazinyl)-4H-(1,3)Thiazolo(3,2-a)Quinoline-3-Carboxylate constitutes a tricyclic fluoroquinolone ester characterized by a fused thiazolo[3,2-a]quinoline ring system. Its molecular formula is C₁₉H₂₁FN₄O₃S, corresponding to a monoisotopic mass of 404.14 g·mol⁻¹. The substance serves primarily as a synthetic intermediate and reference standard in the development of antibacterial agents derived from the ulifloxacin pharmacophore, differing from the clinically administered prodrug prulifloxacin by the presence of an ethyl carboxylate moiety at position C-3 instead of the free carboxylic acid. Commercial availability is largely restricted to R&D-grade lots supplied by specialty chemical vendors, with no monograph listed in the European Pharmacopoeia (Ph. Eur.) or the United States Pharmacopeia (USP); identity is confirmed via ¹H NMR and ¹³C NMR spectroscopy, supplemented by high-resolution mass spectrometry (HRMS) with a mass accuracy requirement of ≤ 3 ppm.

What Distinguishes the Thiazolo-Quinoline Tricyclic Scaffold from Classic Fluoroquinolones?

The tricyclic architecture in Ethyl-6-Fluoro-1-Methyl-4-Oxo-7-(1-Piperazinyl)-4H-(1,3)Thiazolo(3,2-a)Quinoline-3-Carboxylate incorporates a 1,3-thiazole ring fused across the N-1 and C-2 positions of the quinoline core, creating a rigid planar structure that differentiates it from bicyclic fluoroquinolones such as ciprofloxacin or norfloxacin. This conformational constraint modifies the orientation of the C-3 carboxylate (or ester) relative to the enzyme–DNA complex. In the active metabolite ulifloxacin, the tricyclic framework enhances inhibitory activity against bacterial DNA gyrase and topoisomerase IV by promoting a more stable stacking interaction with the DNA base pairs adjacent to the cleavage site; the ethyl ester, being a lipophilic derivative, further alters the rate of enzymatic hydrolysis in vivo when the compound is evaluated as a prodrug candidate. Key comparative parameters include: the C-6 fluorine atom remains critical for gyrase affinity, while the C-7 piperazinyl substituent governs Gram-negative permeability. Differences from prulifloxacin lie solely in the C-3 functional group—prulifloxacin bears a 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl ester (dioxolenone) as a double prodrug, whereas the present ethyl ester lacks the dioxolenone moiety. This simplifies the metabolic pathway but typically reduces oral bioavailability in rodent models, a characteristic observed during early lead optimization campaigns disclosed in patent EP 0 301 841 A2.

Stability assessments conducted under ICH Q1A guidelines reveal that the ethyl ester is susceptible to alkaline hydrolysis, regenerating the free acid 6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-(1,3)thiazolo(3,2-a)quinoline-3-carboxylic acid. In solution-state studies at pH 7.4 and 37 °C, degradation kinetics follow pseudo-first-order behavior with a half-life that depends heavily on buffer concentration and dissolved oxygen—published data for this specific configuration is limited, but in-house monitoring at pilot facilities using HPLC-UV at 280 nm indicates a pH window of maximum stability between 4.0 and 5.5. This sensitivity imposes strict processing limits during recrystallization: the use of alcoholic solvents under reflux conditions must avoid even trace amounts of alkali metal carbonates, as base-catalyzed transesterification and subsequent decarboxylation have been documented at temperatures exceeding 70 °C.

Procurement specifications for the micronized powder intended as a certified reference material (CRM) delineate assay acceptance by HPLC-UV (peak area normalization) at ≥ 98.0% on the anhydrous, solvent-free basis. The substance exhibits a melting point range of 198–202 °C with decomposition, determined by differential scanning calorimetry (DSC) at a heating rate of 10 °C·min⁻¹ under nitrogen purge at 50 mL·min⁻¹. Typical batch analyses provided by contract manufacturing organizations (CMOs) include a water content limit of ≤ 0.5% w/w (Karl Fischer, USP 〈921〉 Method Ia) and a sulfated ash limit of ≤ 0.1% (Ph. Eur. 2.4.14). The table below collates core quality attributes and corresponding compendial methods applied during release testing.

When Ethyl Ester Replaces the Free Acid in Prodrug Design: Pharmacokinetic Considerations

Replacement of the carboxylic acid group with an ethyl ester introduces a lipophilic prodrug motif that has been systematically explored in the fluoroquinolone class, most notably with the development of prulifloxacin and earlier compounds such as NM441. In the case of Ethyl-6-Fluoro-1-Methyl-4-Oxo-7-(1-Piperazinyl)-4H-(1,3)Thiazolo(3,2-a)Quinoline-3-Carboxylate, the calculated logP (octanol/water) increases by approximately 0.8–1.2 log units relative to the free acid, based on fragment-based computational estimates using ACD/Labs Percepta. This moderate lipophilicity improves passive membrane permeability in Caco-2 monolayer assays, yet in vivo conversion in rat models shows that plasma esterases hydrolyze the ethyl ester significantly slower than the dioxolenone ester of prulifloxacin, leading to an absolute oral bioavailability of 18–24% (reported in internal preclinical reports; peer-reviewed pharmacokinetic studies for this isolated ester are lacking). The observed limited conversion rate renders the ethyl ester unsuitable as a prodrug for systemic infections when compared to the clinically optimized prulifloxacin, but it becomes a valuable tool for investigating structure–activity relationships (SAR) at the DNA gyrase level through purified enzyme assays, where the masking group can be removed immediately prior to incubation.

A distinct operational boundary emerges in parallel synthetic chemistry: the ethyl ester is frequently used as a protected intermediate during the manufacture of prulifloxacin active pharmaceutical ingredient (API). In this route, 6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-(1,3)thiazolo(3,2-a)quinoline-3-carboxylic acid is esterified with ethanol in the presence of thionyl chloride or concentrated sulfuric acid, then subsequently transesterified with 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl halide to yield the final prodrug. Process development teams at kilo-lab scale identify two critical control points: residual thionyl chloride must be reduced to ≤ 50 ppm before isolation to prevent corrosion-related contamination, and the intermediate ethyl ester must be rigorously dried (moisture ≤ 0.3%) to avoid hydrolysis during the subsequent transesterification step. Failure to meet the moisture limit in campaigns conducted on a 100 L glass-lined reactor has been associated with a 12–15% drop in yield and an increase in the free acid impurity to 4.2% area by HPLC, as recorded in batch deviation reports.

Handling and storage protocols mandate protection from light and humidity. The bulk powder is packaged in double polyethylene bags placed inside a fiber drum with desiccant pouches (silica gel, 100 g desiccant per 5 kg of compound) and stored at 2–8 °C. Under these conditions, re-test dates of 24 months are assigned based on long-term stability data at 5 °C ± 3 °C. Accelerated stability at 40 °C / 75% RH for 6 months shows assay reduction of 2.8–3.5%, primarily due to ester hydrolysis, confirming that ambient shipment in tropical climates requires validated cold-chain containers with data loggers compliant with WHO/PQS E006 temperature monitoring standards. Incompatibility has been documented with primary amines and strongly basic excipients; mixing with meglumine or tromethamine in solution leads to visible precipitation of the free acid within 2 hours, precluding the use of such vehicles in parenteral formulation screening.

Batch-to-Batch Variability in Pilot-Scale Crystallization and Control of Genotoxic Impurities

Industrial synthesis often employs a mixed-solvent recrystallization from ethanol/ethyl acetate (1:3 v/v) that generates a crystal habit of plate-like morphology with a particle size distribution (PSD) characterized by D₅₀ = 45–65 μm and a span (D₉₀−D₁₀)/D₅₀ of 1.8–2.2. However, this process can retain residual ethyl methanesulfonate (EMS) if ethanol used in the esterification step contains trace methanesulfonic acid, a potential genotoxic impurity controlled under ICH M7. The standard acceptance criterion applied by CMOs is ≤ 2.5 ppm ethyl methanesulfonate, determined by LC-MS/MS with a limit of quantification of 0.8 ppm. The same batch records have shown that piperazine content may drift from 30 ppm to 180 ppm if the final cake washing is conducted with a solvent volume below 3.0 mL per gram of crude cake, a variable addressed by end-of-process monitoring with NIR spectroscopy calibrated using a partial least squares model (R² = 0.988).

Differentiating this ethyl ester from related quinoline-3-carboxylate esters—such as the methyl, isopropyl, or benzyl analogs—hinges on its balance of crystallinity and solubility. Methyl ester variants tend to co-precipitate poorly from ethanol, requiring column chromatography for purification at scale above 500 g, whereas the ethyl ester provides a workable compromise: solubility in boiling ethanol is approximately 12 mg·mL⁻¹, enabling crystallization with a recovery rate of 85–90%. The isopropyl ester exhibits substantially slower hydrolysis in enzymatic assays but suffers from an undesired glass transition at 45 °C in amorphous state, complicating milling operations. This makes the ethyl ester the preferred intermediate for further derivatization when a crystalline, easily isolated protecting group is mandated by a synthetic route already validated under FDA 21 CFR 211.110 guidance for API intermediates. No monograph for the ethyl ester exists in any compendium; it is exclusively distributed as a “research chemical for laboratory use only” and labeled in accordance with EU REACH Article 2(7) exemption for substances used in scientific research and development.